Orally administered griseofulvin has been available for many years, but its usage has been limited because to its narrow spectrum, the need for extensive courses of treatment, low cure rates (about 30%), and high relapse rates. It is the only antifungal drug approved for use in children with onychomycosis in the United States and the United Kingdom. The oral form of ketoconazole is far more effective, although it is associated with the risk of hepatotoxicity.

The use of newer antifungal medicines as part of personalised Onychomycosis Treatment programmes that incorporate patient profiles, nail characteristics, infecting organism(s), potential medication toxicities and interactions, and adjuvant treatments is supported by current research. Triazoles and allylamines are two newer medicines that have become first-line treatments for onychomycosis. These drugs have shorter treatment durations, higher cure rates, and fewer relapses. Terbinafine and itraconazole are the most commonly utilised newer medicines.

Read More- https://coherentmarketinsightsus.blogspot.com/2023/04/there-are-several-types-of.html